TORONTO, March 22, 2021 /CNW/ – Evan Levine, Chief Executive Officer, PsyBio Therapeutics Corp. (“PsyBio” or “the Company”) (TSXV: PSYB) and his team joined Dani Lipkin, Director, Global Business Development, TMX Group to celebrate the Company’s new listing on TSX Venture Exchange and close the market.
PsyBio is a US-based biotechnology company developing a new class of drugs intended for the potential treatment of mental health challenges and other disorders. In collaboration with Miami University based in Oxford, Ohio, PsyBio has retained the global exclusive rights to a proprietary platform technology that biologically synthesizes psilocybin and other targeted next generation psychoactive compounds that are produced naturally in fungi and plants. Management of PsyBio expects that the technology will enable the rapid generation of these highly stable psychoactive compounds cheaper, faster and greener than other published methods. https://www.psybiolife.com/
SOURCE TSX Venture Exchange
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2021/22/c5301.html